Sanofi Net Income 2006-2018 | SNY

Sanofi annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Sanofi net income for the quarter ending March 31, 2018 was $1.249B, a 79.44% decline year-over-year.
  • Sanofi net income for the twelve months ending March 31, 2018 was $4.706B, a 53.34% decline year-over-year.
  • Sanofi annual net income for 2017 was $9.533B, a 82.94% increase from 2016.
  • Sanofi annual net income for 2016 was $5.211B, a 9.47% increase from 2015.
  • Sanofi annual net income for 2015 was $4.76B, a 18.43% decline from 2014.
Sanofi Annual Net Income
(Millions of US $)
2017 $9,533
2016 $5,211
2015 $4,760
2014 $5,836
2013 $4,937
2012 $6,388
2011 $8,265
2010 $7,597
2009 $7,937
2008 $5,666
2007 $7,214
2006 $5,032
2005 $3,229
Sanofi Quarterly Net Income
(Millions of US $)
Q1 2018 $1,249
Q4 2017 $475
Q3 2017 $1,842
Q2 2017 $1,141
Q1 2017 $6,076
Q4 2016 $836
Q3 2016 $1,868
Q2 2016 $1,308
Q1 2016 $1,199
Q3 2015 $1,811
Q2 2015 $1,440
Q2 2014 $1,066
Q2 2013 $580
Q2 2012 $1,505
Q1 2012 $2,414
Q4 2011 $1,887
Q3 2011 $2,803
Q2 2011 $1,453
Q1 2011 $3,187
Q4 2010 $595
Q3 2010 $2,219
Q2 2010 $2,219
Q1 2010 $3,204
Q4 2009 $1,658
Q3 2009 $3,290
Q2 2009 $3,227
Q1 2009 $2,817
Q4 2008 $240
Q3 2008 $1,971
Q2 2008 $2,728
Q1 2008 $2,825
Q4 2007 $2,193
Q3 2007 $2,673
Q2 2007 $1,521
Q1 2007 $2,013
Q4 2006 $742
Q3 2006 $2,178
Q2 2006 $2,250
Q1 2006 $1,819
Q4 2005 $543
Q3 2005 $2,342
Q2 2005 $1,958
Q1 2005 $697
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $110.782B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.718B 18.27
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
Novartis AG (NVS) Switzerland $200.739B 17.21
AbbVie (ABBV) United States $131.784B 11.70
Eli Lilly (LLY) United States $120.858B 21.25
Novo Nordisk (NVO) Denmark $112.280B 18.23
AstraZeneca (AZN) United Kingdom $97.289B 12.08
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13